|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,450.00 KRW | -6.71% |
|
-8.44% | -34.75% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/06/25 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Company Valuation: GC Genome Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 | 2026 | 2027 |
|---|---|---|---|
| Market Cap 1 | 161,298 | 105,246 | - |
| Change | - | -34.75% | - |
| Enterprise Value (EV) 1 | 161.3 | 45.85 | 36.45 |
| Change | - | -71.58% | -20.5% |
| P/E | 36.9x | - | - |
| PBR | - | - | - |
| PEG | -0x | - | - |
| Capitalization / Revenue | - | 2.7x | 2.16x |
| EV / Revenue | - | 1.18x | 0.75x |
| EV / EBITDA | - | - | - |
| EV / EBIT | - | 11.5x | 5.21x |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Dividend per Share 3 | - | - | - |
| Rate of return | - | - | - |
| EPS 3 | 185 | - | - |
| Distribution rate | - | - | - |
| Net sales 1 | - | 39 | 48.8 |
| EBITDA | - | - | - |
| EBIT 1 | - | 4 | 7 |
| Net income | 4.044 | - | - |
| Net Debt 1 | - | -59.4 | -68.8 |
| Reference price 3 | 6,820.00 | 4,450.00 | 4,450.00 |
| Nbr of stocks (in thousands) | 23,651 | 23,651 | - |
| Announcement Date | 16/03/26 | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | 1.37x | - | - | 75.13M | ||
| -162.47x | 13.45x | -183.51x | -.--% | 38.66B | ||
| 19.1x | 1.86x | 10.7x | 1.05% | 22.7B | ||
| 17.02x | 1.33x | 7.56x | 5.11% | 7.3B | ||
| 336.41x | - | - | - | 5.16B | ||
| 48.03x | 8.54x | 30.33x | 1.08% | 2.97B | ||
| -21.9x | - | - | - | 1.95B | ||
| 32.09x | 1.15x | 9.57x | 0.79% | 1.84B | ||
| -31.66x | - | - | -.--% | 1.84B | ||
| 12.91x | 1.34x | 5.24x | 5.86% | 1.75B | ||
| Average | 27.73x | 4.15x | -20.02x | 1.98% | 8.42B | |
| Weighted average by Cap. | -45.92x | 7.99x | -88.81x | 0.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A340450 Stock
- Valuation GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions
















